NMTC (NMTC) CTO uses 906 shares of common stock to cover tax liability

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mertens Steve

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	906	$0.777	$703.96

Holdings After Transaction: Common Stock — 152,141 shares (Direct)

Footnotes (1)

Key Figures

Tax-withholding shares: 906 shares Tax-withholding price: $0.777 per share Shares held after transaction: 152,141 shares

3 metrics

Tax-withholding shares 906 shares Shares delivered for tax liability under code F

Tax-withholding price $0.777 per share Valuation used for 906 withheld shares

Shares held after transaction 152,141 shares Direct common stock holdings after tax-withholding disposition

Key Terms

tax-withholding disposition, Payment of exercise price or tax liability by delivering securities, Form 4

3 terms

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Payment of exercise price or tax liability by delivering securities financial

"transaction_code_description: "Payment of exercise price or tax liability by delivering securities""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mertens Steve

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		F		906	D	$0.777	152,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NMTC CTO Steve Mertens report on this Form 4?

Steve Mertens reported a tax-withholding disposition of NMTC shares. On the transaction date, 906 shares of common stock were delivered at $0.777 per share to cover a tax liability, rather than representing an open-market sale of stock.

How many NEUROONE (NMTC) shares were involved in the CTO’s tax withholding?

The filing shows 906 shares of NEUROONE common stock used for tax withholding. These shares were valued at $0.777 per share for this purpose, reflecting a routine mechanism to satisfy tax obligations tied to equity compensation.

Did NMTC’s CTO sell shares on the open market in this Form 4?

No, the Form 4 describes a tax-withholding disposition, not an open-market sale. Shares were delivered to satisfy a tax liability associated with equity compensation, which is a common administrative transaction rather than a discretionary market trade.

How many NMTC shares does the CTO hold after this reported transaction?

After the tax-withholding disposition, Steve Mertens directly holds 152,141 shares of NEUROONE common stock. This figure reflects his direct ownership position following the delivery of 906 shares to cover the related tax obligation.

What does transaction code F mean in the NMTC CTO Form 4 filing?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this NMTC filing, it shows 906 shares of common stock were used to satisfy a tax obligation, rather than being bought or sold on the open market.